Blab Business
Medtronic Nears Dividend-King Status as Spin-Off and Earnings Outlook Support Future Increases
Medtronic plc (NYSE: MDT) is on the brink of becoming a Dividend King, a title reserved for companies that have raised dividends for 50 consecutive years. The medical‑device maker has already increased its dividend for 49 straight years and is expected to raise it again in June 2027, the company’s next scheduled dividend declaration.
The company’s current payout ratio is estimated at 45% for the fiscal year that ends in April 2026, according to market‑beat estimates. That figure is well below the 70‑plus percent range that Medtronic has historically maintained, leaving room for a modest increase without overextending its finances. The dividend yield is 3.16% and the five‑year dividend growth rate is 4.13%, both figures that place Medtronic among the more reliable income stocks in the healthcare sector.
Medtronic’s most recent dividend hike was 1.4%, the smallest increase in several years. The company’s board has indicated that a modest rise next June would be feasible, given the current payout ratio and the company’s cash‑flow profile. The ex‑dividend date for the upcoming payment is June 26, 2026, and the dividend per share for the current fiscal year is $2.88.
A key factor in Medtronic’s dividend outlook is the spin‑off of its diabetes‑technology business, MiniMed Group (NASDAQ: MMED). The spin‑off was completed in March 2026, with Medtronic retaining a 90% stake in the new company. CEO Geoff Martha has said the company intends to reduce that stake to zero over time. MiniMed’s fiscal year that ended in April 2026 reported negative cash flow, a result of separation costs and the build‑out of a stand‑alone entity.
If Medtronic completes the divestiture while MiniMed remains unprofitable, the parent company could see an improvement in its own cash‑flow position. That would provide additional flexibility for dividend increases. The company continues to include MiniMed’s results in its full‑year forecasts, so the timing of the final sale remains unclear.
Beyond the spin‑off, Medtronic’s earnings guidance points to a resurgence in growth. The company’s product pipeline includes several next‑generation cardiac and neuro‑stimulation devices, and its global reach in more than 150 countries supports a steady revenue stream. Analysts note that the company’s large, diversified portfolio could sustain dividend growth even if the pace of earnings expansion slows.
Investors looking for income will note that Medtronic’s dividend history is solid but not spectacular. The company’s dividend per share has grown steadily, and the yield remains attractive relative to other large‑cap healthcare names. However, the company’s share price has not delivered the same level of capital appreciation as some of its peers, which may limit its appeal to investors seeking both income and growth.
In summary, Medtronic is poised to achieve Dividend‑King status in June 2027 if it declares a dividend increase. The company’s payout ratio, cash‑flow profile, and ongoing growth prospects support a modest hike. The spin‑off of MiniMed adds uncertainty to the timing of a full divestiture, but it also offers a potential boost to Medtronic’s cash position. Investors should monitor the company’s next earnings release and dividend declaration for confirmation.
The next key dates for Medtronic investors are the ex‑dividend date of June 26, 2026, and the dividend declaration expected in July 2026. The company’s upcoming earnings report will provide further insight into its cash‑flow health and the likelihood of a dividend increase that would cement its status as a Dividend King.
The company’s current payout ratio is estimated at 45% for the fiscal year that ends in April 2026, according to market‑beat estimates. That figure is well below the 70‑plus percent range that Medtronic has historically maintained, leaving room for a modest increase without overextending its finances. The dividend yield is 3.16% and the five‑year dividend growth rate is 4.13%, both figures that place Medtronic among the more reliable income stocks in the healthcare sector.
Medtronic’s most recent dividend hike was 1.4%, the smallest increase in several years. The company’s board has indicated that a modest rise next June would be feasible, given the current payout ratio and the company’s cash‑flow profile. The ex‑dividend date for the upcoming payment is June 26, 2026, and the dividend per share for the current fiscal year is $2.88.
A key factor in Medtronic’s dividend outlook is the spin‑off of its diabetes‑technology business, MiniMed Group (NASDAQ: MMED). The spin‑off was completed in March 2026, with Medtronic retaining a 90% stake in the new company. CEO Geoff Martha has said the company intends to reduce that stake to zero over time. MiniMed’s fiscal year that ended in April 2026 reported negative cash flow, a result of separation costs and the build‑out of a stand‑alone entity.
If Medtronic completes the divestiture while MiniMed remains unprofitable, the parent company could see an improvement in its own cash‑flow position. That would provide additional flexibility for dividend increases. The company continues to include MiniMed’s results in its full‑year forecasts, so the timing of the final sale remains unclear.
Beyond the spin‑off, Medtronic’s earnings guidance points to a resurgence in growth. The company’s product pipeline includes several next‑generation cardiac and neuro‑stimulation devices, and its global reach in more than 150 countries supports a steady revenue stream. Analysts note that the company’s large, diversified portfolio could sustain dividend growth even if the pace of earnings expansion slows.
Investors looking for income will note that Medtronic’s dividend history is solid but not spectacular. The company’s dividend per share has grown steadily, and the yield remains attractive relative to other large‑cap healthcare names. However, the company’s share price has not delivered the same level of capital appreciation as some of its peers, which may limit its appeal to investors seeking both income and growth.
In summary, Medtronic is poised to achieve Dividend‑King status in June 2027 if it declares a dividend increase. The company’s payout ratio, cash‑flow profile, and ongoing growth prospects support a modest hike. The spin‑off of MiniMed adds uncertainty to the timing of a full divestiture, but it also offers a potential boost to Medtronic’s cash position. Investors should monitor the company’s next earnings release and dividend declaration for confirmation.
The next key dates for Medtronic investors are the ex‑dividend date of June 26, 2026, and the dividend declaration expected in July 2026. The company’s upcoming earnings report will provide further insight into its cash‑flow health and the likelihood of a dividend increase that would cement its status as a Dividend King.
